ClinicalTrials.gg
CompletedNCT04189848Updated Nov 7, 2022Results posted

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

A Phase 4 interventional study of Semaglutide and Dulaglutide in Healthy Volunteers, Diabetes Mellitus, Type 2 and Overweight, sponsored by Novo Nordisk A/S. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
82nd of 163
104 · median 104
Started
2019
with 17 others
Phase 4
40 of 163
17 open now
Registered
70th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 82nd largest by enrollment, is one of 18 that started in 2019, is one of 40 in phase 4, and was the 70th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

03

Conditions studied

  • Healthy Volunteers
  • Diabetes Mellitus, Type 2
  • Overweight
  • Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
  • equal to or above 25.0 kg/m\^2.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial product(s) or related products.
  • Previous participation in trial INS-4603, INS-4582 or NN9535-4648. Participation is defined as having received product.
  • Female who is pregnant, breast-feeding or intends to become pregnant within 4 weeks of Day 1 or is of and not using highly effective methods.
  • Participation in a drug study within 60 days prior to drug administration in the current trial OR participation in more than 4 other drug studies in the 12 months prior to drug administration in the current trial.
  • Any disorder which in the Investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol.
  • Glycosylated () equal to or above 6.5 % (48 mmol/mol) at screening.
  • Supine blood pressure at screening (after resting for 5 minutes or longer) outside the range of 90-160 mmHg for systolic or 45-89 mmHg for diastolic.
  • Supine pulse rate (as part of vital signs) outside the range of 40-100 beats/min after resting for 5 minutes or longer at screening.
  • Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, contraceptives and occasional use of paracetamol (not allowed within 24 hours prior to drug administration), within 14 days prior to Day 1.
  • Diagnostic test results positive for -1 or HIV-2 infection.
  • Diagnostic test results positive for active or infection.
  • Mental incapacity, language barriers, or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the trial as judged by the Investigator.
  • Average intake of more than 21 units of alcohol per week for male subjects and more than 14 units per week for female subjects: 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
  • Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening and admission to the clinical research centre.
  • Use of tobacco and nicotine products, defined as any of the below:
  • Smoking more than 1 cigarette or the equivalent per day on average.
  • Not able or willing to refrain from smoking and use of nicotine substitute products during the in-house period.
  • Blood donation, plasma donation, or blood draw
  • In excess of 400 mL within the past 90 days prior to the day of screening
  • In excess of 50 mL within the past 30 days prior to the day of screening
  • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
  • Subjects with a history of malignant neoplasms within the past 5 years prior to screening will be excluded from the trial.
  • Presence or history of pancreatitis (acute or chronic; as declared by the subject or reported in the medical records).
  • Subject is not able to understand and read English or Dutch, or subject is not able to understand and comply with the trial requirements.
  • Subject depends on the Sponsor, the Investigator, or the study centre, or subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the trial.
  • Vulnerable subject (e.g. person kept in detention) who may have an increased likelihood of being wronged or of incurring additional harm.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Semaglutide followed by dulaglutide

    The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach

    Drug: Semaglutide · Drug: Dulaglutide

  • Experimental
    Dulaglutide followed by semaglutide

    The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach

    Drug: Semaglutide · Drug: Dulaglutide

Interventions

  • Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

  • Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

06

What researchers measure

Primary outcomes

  1. Intensity of Injection Site Pain

    The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed.

    Time frame: 1 minute after each injection (Day 1)

07

Results

Posted Feb 17, 2021

Participant flow

The trial was conducted at one site in the Netherlands.

Treatment Period 1 (Day 1)
Participant flow — Treatment Period 1 (Day 1)
MilestoneSequence A: Semaglutide (Right) Then Dulaglutide (Left)Sequence B: Semaglutide (Left) Then Dulaglutide (Right)Sequence C: Dulaglutide (Right) Then Semaglutide (Left)Sequence D: Dulaglutide (Left) Then Semaglutide (Right)
Started26262527
Completed26262527
Not completed0000
Treatment Period 2 (Day 1)
Participant flow — Treatment Period 2 (Day 1)
MilestoneSequence A: Semaglutide (Right) Then Dulaglutide (Left)Sequence B: Semaglutide (Left) Then Dulaglutide (Right)Sequence C: Dulaglutide (Right) Then Semaglutide (Left)Sequence D: Dulaglutide (Left) Then Semaglutide (Right)
Started26262527
Completed26262527
Not completed0000

Outcome measures

PrimaryIntensity of Injection Site Pain

The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed.

Time frame:
1 minute after each injection (Day 1)
Reported as:
Mean · Score on a scale
Intensity of Injection Site Pain
Score on a scaleSemaglutideDulaglutide
Intensity of Injection Site Pain5.6 ± 10.111.5 ± 12.8
Statistical analysis
  • Semaglutide vs Dulaglutide · ANOVA · p = <0.0001 · Treatment difference: -5.9 · 95% CI -8.2 to -3.6

Adverse events

Collected over Day 1 to Day 28. Results are based on the safety analysis set which included all participants who had received at least 1 injection of semaglutide or dulaglutide (included any skin contact with trial product whether the injection was completed or not).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Study0/104 (0%)0/104 (0%)34/104 (32.7%)
Most frequent other events
Most frequent other events
EventOverall Study
NauseaGastrointestinal disorders22/104
Decreased AppetiteMetabolism and nutrition disorders12/104

Baseline characteristics

Full analysis set (FAS) included all randomised subjects who had received at least 1 injection of semaglutide or dulaglutide (included any skin contact with trial product whether the injection was completed or not).

Age, Continuous
Age, Continuous(years)Overall Study
Mean36.9 ± 17.5
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female62
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino0
Not Hispanic or Latino104
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
Race — White + Black or African5
Race — Asian3
Race — Black or African American1
Race — White94
Race — White + Asian1
08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Groningen, 9728 NZ, Netherlands
09

References and documents

Publications

  • Snitker S, Andersen A, Berg B, van Marle S, Sparre T. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects. Diabetes Obes Metab. 2021 Jun;23(6):1415-1419. doi: 10.1111/dom.14349. Epub 2021 Mar 18. PubMed 33591618 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jan 2020, 1 month.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 1 month is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 6, 2019
StartActual
Dec 3, 2019
Primary completionActual
Jan 29, 2020
CompletionActual
Feb 27, 2020
Results first posted
Feb 17, 2021
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04189848
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 6, 2019
Start date
Dec 3, 2019
Primary completion
Jan 29, 2020
Completion
Feb 27, 2020
Results posted
Feb 17, 2021
Last update
Nov 7, 2022

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion